ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Einhorn Begins Term; Salmon, Blum Honored; Gore Gives Award To IntraMall, Piloted At NCI.

May 26, 2000

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975

Clinical Trials Approved By NCI

January 30, 2004

In Brief: BMS Chemistry Awards to Honor Fu, Wood; Groshow Joins NCI; Bowman Moves to TJU

January 15, 1999

Critics Told To Back Waste Charges Or Shut Up

November 23, 1974

NCI Get Go-Ahead For New Cancer Control Projects Totaling $7.4 Million, Funded By Grants, Contracts

October 21, 1977